Drugs / MiSaver
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04050163 | Jan 2021 → May 2023 | myocardial infarction | Honya Medical Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07134712 | Mar 2026 → Dec 2027 expected | acute myocardial infarction | Honya Medical Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MiSaver | “MiSaver, a cellular therapy product” NCT07134712 ↗ |
| Known as | Umbilical Cord Blood Derived Nucleated Cells | “MiSaver (Umbilical Cord Blood Derived Nucleated Cells)” NCT07134712 ↗ |
| Modality | Cell therapy | “MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)” NCT04050163 ↗ |
| Route | Intravenous | “Intravenous administration of MiSaver® Stem Cell via peripheral vein access.” NCT04050163 ↗ |